These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7937556)

  • 1. Bioequivalence: performance of several measures of rate of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 Jul; 11(7):966-74. PubMed ID: 7937556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.
    el-Tahtawy AA; Tozer TN; Harrison F; Lesko L; Williams R
    Pharm Res; 1998 Jan; 15(1):98-104. PubMed ID: 9487554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax.
    el-Tahtawy AA; Jackson AJ; Ludden TM
    Pharm Res; 1995 Nov; 12(11):1634-41. PubMed ID: 8592662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption rate vs. exposure: which is more useful for bioequivalence testing?
    Tozer TN; Bois FY; Hauck WW; Chen ML; Williams RL
    Pharm Res; 1996 Mar; 13(3):453-6. PubMed ID: 8692741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.
    Karlsson MO; Bredberg U
    J Pharmacokinet Biopharm; 1990 Apr; 18(2):103-20. PubMed ID: 2348378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.
    Mangas-Sanjuan V; Navarro-Fontestad C; García-Arieta A; Trocóniz IF; Bermejo M
    Eur J Pharm Sci; 2018 May; 117():193-203. PubMed ID: 29452210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bioequivalence assessment of pioglitazone hydrochloride oral preparation by limited sampling strategy].
    Ding JJ; Jiao Z; Li ZD; Shi XJ
    Yao Xue Xue Bao; 2006 Sep; 41(9):893-8. PubMed ID: 17111840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations.
    el-Tahtawy AA; Jackson AJ; Ludden TM
    Pharm Res; 1994 Sep; 11(9):1330-6. PubMed ID: 7816765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of truncated areas to measure extent of drug absorption in bioequivalence studies: effects of drug absorption rate and elimination rate variability on this metric.
    Kharidia J; Jackson AJ; Ouderkirk LA
    Pharm Res; 1999 Jan; 16(1):130-4. PubMed ID: 9950291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
    Jackson AJ
    Pharm Res; 2000 Nov; 17(11):1432-6. PubMed ID: 11205739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence.
    Zha J; Endrenyi L
    J Biopharm Stat; 1997 Mar; 7(1):191-204. PubMed ID: 9056598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.
    Gaudreault J; Potvin D; Lavigne J; Lalonde RL
    Pharm Res; 1998 Oct; 15(10):1621-9. PubMed ID: 9794507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.